Novartis | NVS - Actif À Court Terme





Actif À Court Terme Changement Date
AbbVie USD 33.53B 4.47B 2026-03
Amgen USD 31.48B 2.42B 2026-03
AstraZeneca USD 29.61B 890M 2026-03
Bausch Health Companies USD 5.98B 179M 2026-03
Biogen USD 9.19B 216.3M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Canopy Growth CAD 524.67M 78.85M 2025-12
Corcept Therapeutics USD 426.03M 59.43M 2026-03
Drreddys Laboratories INR 3.31B 164.26M 2025-12
Eli Lilly USD 54.84B 794M 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
GlaxoSmithKline GBP 17.76B 251M 2026-03
Glaxosmithkline GBP 23.59B 390.44M 2025-12
J&J USD 59.17B 3.55B 2026-03
Merck USD 35.02B 8.5B 2026-03
Novartis USD 26.61B 3.85B 2026-03
Novartis USD 30.46B 2.26B 2025-12
Pacira USD 514.96M 33.01M 2026-03
Perrigo USD 2.71B 85M 2026-03
Pfizer USD 42.82B 76M 2026-03
Phibro Animal Health USD 894.07M 31.88M 2026-03
Prestige Brands USD 431.48M 1.94M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Sanofi EUR 30.16B 789M 2026-03
Sanofi EUR 30.95B 8.99B 2025-12
Supernus Pharmaceuticals USD 731.58M 87.4M 2026-03
Zoetis USD 6.47B 294M 2026-03